-0.52%
6.25%
-9.85%
-27.00%
-33.57%
-34.40%
-19.50%
AI Spotlight on CRSP
Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies.In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases.
It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Market Data
| Last Price | 41.82 |
| Change Percentage | -0.52% |
| Open | 42.05 |
| Previous Close | 42.04 |
| Market Cap ( Millions) | 3569 |
| Volume | 1674535 |
| Year High | 91.1 |
| Year Low | 36.52 |
| M A 50 | 44.42 |
| M A 200 | 50.38 |
Financial Ratios
| FCF Yield | -5.36% |
| Dividend Yield | 0.00% |
| ROE | -12.15% |
| Debt / Equity | 11.73% |
| Net Debt / EBIDTA | -0.60% |
| Price To Book | 1.84 |
| Price Earnings Ratio | -14.88 |
| Price To FCF | -18.67 |
| Price To sales | 17.7 |
| EV / EBITDA | -11.41 |
News
- Jan -29 - CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
- Jan -27 - DeepSeek AI picks 2 stocks to buy and hold forever
- Jan -24 - CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- Jan -23 - My Top 5 Stocks to Buy in Early 2025
- Jan -17 - CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
- Jan -16 - 2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
- Jan -16 - My 10 Top Stocks to Buy to Start the New Year Off Right
- Jan -16 - CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
- Jan -15 - CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
- Jan -15 - CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
- Jan -14 - Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
- Jan -09 - 3 Mid-Cap Stocks That Could Take Off in 2025
- Jan -08 - CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan -07 - CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
- Jan -07 - 2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
- Dec -31 - CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
- Dec -29 - Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
- Dec -27 - CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
- Dec -23 - Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
- Dec -22 - This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Collaboration
Expected Growth : 15.0 %
What the company do ?
CRISPR Therapeutics AG collaborates with Vertex Pharmaceuticals to develop gene-editing therapies for beta-thalassemia and sickle cell disease.
Why we expect these perspectives ?
CRISPR Therapeutics AG's 15.0% growth is driven by increasing adoption of gene editing technologies, strategic collaborations, and a strong pipeline of novel therapies. The company's pioneering CRISPR-Cas9 platform has attracted partnerships with leading biopharmaceutical companies, expanding its reach and accelerating innovation. Additionally, growing investments in research and development, and a favorable regulatory environment, contribute to the company's rapid growth.
Segment n°2 -> Grant
Expected Growth : 14.43 %
What the company do ?
CRISPR Therapeutics AG received a grant to support the development of CRISPR-Cas9 gene editing technology for treating genetic diseases.
Why we expect these perspectives ?
The 14.43% growth driven by CRISPR Therapeutics AG's grant is attributed to increasing adoption of gene editing technologies, strategic partnerships, and investments in research and development. Additionally, growing demand for novel therapeutic approaches and expanding applications in oncology, rare genetic diseases, and regenerative medicine contribute to the company's rapid growth.
Crispr Therapeutics Ag Products
| Product Range | What is it ? |
|---|---|
| CRISPR-Cas9 Gene Editing | A precise genome editing tool that enables precise double-strand breaks in DNA, allowing for efficient and specific editing of genes |
| CRISPR-Cpf1 Gene Editing | A novel genome editing tool that offers improved efficiency and flexibility compared to CRISPR-Cas9, with potential applications in gene therapy and regenerative medicine |
| Allogenic CAR-T Cell Therapy | A type of immunotherapy that uses genetically modified T cells to target and kill cancer cells, with potential applications in treating various types of cancer |
| Autologous CAR-T Cell Therapy | A personalized immunotherapy approach that uses a patient's own T cells to target and kill cancer cells, with potential applications in treating various types of cancer |
| Gene-Edited Stem Cell Therapies | A novel approach that combines gene editing with stem cell therapy to treat genetic diseases and disorders |
CRISPR Therapeutics AG's Porter Forces
Threat Of Substitutes
CRISPR Therapeutics AG has a low threat of substitutes due to its unique gene-editing technology, which is difficult to replicate.
Bargaining Power Of Customers
CRISPR Therapeutics AG has a medium bargaining power of customers, as it has a strong pipeline of products, but customers may have some bargaining power due to the competitive landscape.
Bargaining Power Of Suppliers
CRISPR Therapeutics AG has a low bargaining power of suppliers, as it has a strong supply chain and is not heavily reliant on a single supplier.
Threat Of New Entrants
CRISPR Therapeutics AG has a high threat of new entrants, as the gene-editing space is highly competitive and new companies are entering the market.
Intensity Of Rivalry
CRISPR Therapeutics AG operates in a highly competitive industry, with many established players and new entrants, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 11.25% |
| Debt Cost | 3.95% |
| Equity Weight | 88.75% |
| Equity Cost | 12.91% |
| WACC | 11.90% |
| Leverage | 12.67% |
CRISPR Therapeutics AG : Quality Control
CRISPR Therapeutics AG passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
| MRUS | Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Genmab
A-Score
1-Year Total Return ->
🥈
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Alkermes
A-Score
1-Year Total Return ->
4
Zealand Pharma
A-Score
1-Year Total Return ->
5
Merus
A-Score
1-Year Total Return ->
6
